Sugi Predict

Sugi Predict / Compounds / SCHEMBL4477648

SCHEMBL4477648

SCHEMBL4477648

Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 15/20 1.00
▸ FLT3 P36888 10/20 0.78
▸ CSF1R P07333 7/20 0.78
▸ FGFR1 P11362 7/20 0.78
▸ RPS6KB1 P23443 7/20 0.78
▸ PLK4 O00444 6/20 0.78
▸ AURKA O14965 6/20 0.78
▸ ROCK2 O75116 6/20 0.78
▸ LCK P06239 6/20 0.78
▸ LYN P07948 6/20 0.78
▸ BLK P51451 6/20 0.78
▸ RPS6KA3 P51812 6/20 0.78
▸ NEK2 P51955 6/20 0.78
▸ STK3 Q13188 6/20 0.78
▸ ROCK1 Q13464 6/20 0.78
▸ NTRK2 Q16620 6/20 0.78
▸ MARK2 Q7KZI7 6/20 0.78
▸ RET P07949 6/20 0.78
▸ FLT1 P17948 6/20 0.78
▸ AXL P30530 6/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467381 0.89 KIT (0.82) KDRFLT3CSF1RFGFR1RPS6KB1
SCHEMBL4474877 0.89 KDR (0.80) KDRFLT3CSF1RFGFR1RPS6KB1
SCHEMBL4486611 0.88 KDR (1.00) KDRFLT3CSF1RFGFR1RPS6KB1
SCHEMBL4477423 0.88 KDR (0.78) KDRFLT3CSF1RFGFR1RPS6KB1
SCHEMBL4478814 0.88 KDR (0.78) KDRFLT3CSF1RFGFR1RPS6KB1
SCHEMBL232042 0.88 KDR (1.00) KDRFLT3CSF1RFGFR1RPS6KB1
SCHEMBL4466145 0.87 KDR (0.79) KDRFLT3CSF1RFGFR1RPS6KB1
SCHEMBL4472448 0.87 KDR (0.80) KDRFLT3CSF1RFGFR1RPS6KB1
SCHEMBL4721391 0.86 PLK4 (0.78) KDRFLT3CSF1RFGFR1RPS6KB1
SCHEMBL4471717 0.86 KDR (0.83) KDRFLT3CSF1RFGFR1RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 — — US claimed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US claimed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 — — US claimed
US-20030181468-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-09-25 — — US claimed
EP-1487841-B1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBVIE INC (US) 2014-01-15 — — EP disclosed
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 — — US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 — — US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US disclosed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 — — US disclosed
US-20030181468-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885FLT3 29/4885CSF1R 1295/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KDR 391/4885FLT3 16/4885CSF1R 1647/4885
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885FLT3 29/4885CSF1R 1295/4885
US-20030181468-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 462/4885FLT3 44/4885CSF1R 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.